Merck vs Roche

Target earnings, Canada tariffs, American Airlines screens

CNBC’s Morning Squawk highlights market-moving items on Aug. 19, 2026: Moderna shares jumped as much as 100% after a personalized cancer vaccine developed with Merck showed positive late-stage results. Global bond yields have spiked, pressuring stocks and mortgage rates ahead of Fed minutes and the Jackson Hole conference. Retailers saw tariff refunds boost earnings: Target said refunds added $752 million to Q2 net earnings and raised its full-year outlook; Lowe’s credited an 11-cent EPS lift but gave a tepid outlook and missed revenue expectations. President Trump paused planned 50% tariffs on certain Canadian goods for three days pending final documents. American Airlines announced plans to add seatback screens to most narrow-body aircraft starting in 2028. Auto dealers are emphasizing parts and services as new-vehicle sales soften.

• Moderna shares rose as much as 100% after a personalized cancer vaccine it developed with Merck showed positive results in its first late-stage trial.
• Target said tariff refunds boosted its net earnings by $752 million in the second quarter and raised its full-year outlook.
• Lowe’s credited tariff refunds for an 11 cent increase in EPS but issued a tepid full-year outlook and missed second-quarter revenue expectations.

AI-Personalized Cancer Vaccine Halves Melanoma Recurrence

The AI Secret newsletter highlights multiple AI and tech developments: Merck and Moderna said their personalized mRNA cancer vaccine, intismeran autogene, met endpoints in a 1,000-patient melanoma Phase 3 trial, cutting recurrence by half and reducing metastasis by 59%. Cursor launched Origin, a GitHub rival interoperable with GitHub and reportedly backed by Elon Musk, coinciding with a major GitHub outage. OpenAI changed how ChatGPT sources information—moving to a site:operator approach that reduced Reddit citations and appears to centralize which sources are surfaced, opening the door to paid or prioritized signals. Etched raised $700 million at a $21 billion valuation, backed by Jane Street, to build custom inference chips. The newsletter also includes a sponsored mention of MyClaw (an AI agent hosting platform) and a brief TL;DR of other AI-industry developments.

• Merck and Moderna announced that intismeran autogene met endpoints in a 1,000-patient melanoma Phase 3 trial, halving recurrence and reducing distant metastasis by 59% with no new side effects.
• Cursor launched Origin, a GitHub-compatible code-hosting platform, the same day GitHub experienced a six-hour global outage.
• OpenAI changed ChatGPT's retrieval approach in early August to use a site:operator starting point, which reduced Reddit citations from ~4.5% to ~0.5% and increased site:operator usage in queries from 0.37% to 16.8% (PromptWatch data).

Wirz Launches Healthcare Consulting Unit Wirz Pulse

Swiss agency group Wirz has launched 'Wirz Pulse', a specialized consulting offering for the healthcare market, targeting hospitals, insurers, and pharma/medtech companies. The service aims to support healthcare organizations in positioning, change management, and growth. Wirz will collaborate with organizations to develop a strategic direction translated into positioning, culture, offerings, communication, and experiences. Six programs cover transformation, brand identity, patient journey, work culture, innovation, and digital experience. The launch responds to labor shortages, cost pressure, digitalization, and evolving patient needs, as well as new fields like personalized medicine and longevity. Existing healthcare mandates include Roche, University Hospital Zurich, CSS, Interpharma, and Rheumaliga Schweiz, from which Wirz derived recurring challenges and success factors.

• Wirz Group launches 'Wirz Pulse' consulting service for healthcare sector.
• Targets hospitals, insurers, pharma, and medtech companies.
• Offers six programs: transformation, brand identity, patient journey, work culture, innovation, digital experience.

Roche and Ypsomed Stay Top in Swiss Reputation Ranking

Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method to evaluate media reputation for 40 pharma and medtech companies. The study measured presence (coverage and reach) and tonality (positive/negative reporting) and calculated a Reputation Score (0–100) for each company across six reputation dimensions. In Pharma & Biopharma, Roche ranks first (ahead of MSD, Novartis, Sandoz and AstraZeneca). In MedTech & Diagnostics, Ypsomed remains first (ahead of Medacta, Straumann Group, Alcon and Sonova). The study notes products/services, innovation and economic performance tended to improve media reputation, while workplace issues (layoffs, relocations) and ESG/legal problems harmed reputation. The article was published on 2026-08-13.

• Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method.
• The study measured presence and tonality for 40 pharma and medtech companies and computed a Reputation Score between 0 and 100 across six reputation dimensions.
• In the Pharma & Biopharma category, Roche ranked first, followed by MSD, Novartis, Sandoz and AstraZeneca.

Roche Pharma Day 2026 announced

Roche Pharma Day 2026 will be held on Monday, 28th September 2026, 09:00am BST. More details available via the investor update.